Outcome
    Moderate Evidence

    Pygeum for Prostate Health

    Pygeum shows modest but real improvements in nocturia and urinary flow.

    Overview

    Pygeum africanum bark extract has a long European history in benign prostatic hyperplasia, and a Cochrane review of 18 randomised trials found moderate improvement in urological symptoms and flow measures compared with placebo. Men were roughly twice as likely to report overall symptom improvement. The realistic expectation is fewer night-time trips to the bathroom and a somewhat better stream, not a reduction in prostate size.
    The main weakness of the evidence is age and scale. Most trials were conducted before modern standards, ran only 30 to 120 days, and used small samples with inconsistent outcome reporting. No large contemporary trial has replicated the findings. That is why the verdict is likely rather than strong, and why pygeum sits alongside, not instead of, a urological assessment. Lower urinary tract symptoms can also arise from prostate cancer, infection or bladder dysfunction.

    How It Works

    Pygeum bark contains phytosterols, principally beta-sitosterol, along with pentacyclic triterpenes and ferulic acid esters. Beta-sitosterol inhibits prostaglandin synthesis in prostatic tissue, reducing the local inflammation that contributes to swelling and irritative symptoms. The triterpenes appear to reduce oedema by inhibiting glucosyltransferase activity and stabilising capillary permeability.
    Laboratory work also shows inhibition of fibroblast growth factor and epidermal growth factor stimulated proliferation of prostatic fibroblasts, offering a plausible route to limiting stromal overgrowth. Unlike finasteride, pygeum does not meaningfully inhibit 5-alpha reductase, so it does not lower serum DHT or PSA. That is clinically useful, because it does not mask the PSA readings used in cancer screening.

    Dosing & Protocol

    The standard trial dose is 100 mg per day of standardised bark extract, either as 50 mg twice daily or 100 mg once daily. A randomised comparison found the once-daily form equivalent to the twice-daily regimen, which helps adherence. Symptom change is typically assessed at 8 to 12 weeks. Products should state standardisation, since bark extract potency varies widely.

    Get symptoms assessed first

    Urinary symptoms need a clinical evaluation including PSA discussion. Do not treat blood in urine, retention, or new severe symptoms with a supplement.

    Evidence

    Three linked sources define this pairing: the 2002 Cochrane review of Pygeum africanum for benign prostatic hyperplasia, a 2000 systematic review and quantitative meta-analysis in the American Journal of Medicine, and a 1999 randomised double-blind comparison of once versus twice daily dosing in Urology. Cochrane concluded that pygeum modestly improves urological symptoms and flow, while noting that the trials were small, short and of variable quality.

    Studies linked to this pairing.

    Pygeum africanum for benign prostatic hyperplasia

    Score: 8/10
    2002
    systematic_review
    n=1562

    Wilt T, Ishani A, Mac Donald R +2 more

    Across 18 randomised trials Pygeum africanum improved urologic symptoms and peak urine flow versus placebo, with adverse events comparable to placebo.

    View source

    Pygeum africanum for the treatment of patients with benign prostatic hyperplasia: a systematic review and quantitative meta-analysis

    Score: 7/10
    2000
    meta_analysis
    n=1562

    Ishani A, MacDonald R, Nelson D +2 more

    Men taking Pygeum africanum were more than twice as likely to report improved overall symptoms, with reduced nocturia and residual urine volume.

    View source

    Comparison of once and twice daily dosage forms of Pygeum africanum extract in patients with benign prostatic hyperplasia: a randomized, double-blind study

    Score: 5/10
    1999
    rct
    n=209

    Chatelain C, Autet W, Brackman F

    Both 100 mg once daily and 50 mg twice daily reduced IPSS by about 38 percent with benefit maintained one month after withdrawal.

    View source

    Safety

    Pygeum is well tolerated. Withdrawal rates in the reviewed trials were similar to placebo, and reported side effects were mild gastrointestinal complaints such as nausea, stomach pain and diarrhoea. Long-term safety data beyond a few months are limited. There is also a conservation issue worth knowing: wild Pygeum africanum is CITES-listed, so sustainably sourced or cultivated material is preferable.

    It does not lower PSA

    Unlike finasteride, pygeum does not suppress PSA, so it will not mask prostate cancer screening results.

    Interactions & Conflicts

    No significant pharmacokinetic interactions have been documented. The practical conflicts are clinical rather than chemical: taking pygeum alongside alpha blockers or 5-alpha reductase inhibitors makes it impossible to attribute any improvement, and self-treating can delay assessment of symptoms with a serious cause. Supplement quality also varies substantially, so unstandardised products may deliver little active material.
    Interacts withSeverityMechanismAction
    low
    		——
    low
    		——
    low
    		——
    high
    		——

    References

    Frequently Asked Questions

    Medical Disclaimer

    The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

    Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.